Different facets of copy number changes: Permanent, transient, and adaptive

Molecular and Cellular Biology

Volumn 36, Issue 7, 2016, Pages 1050-1063

  Mishra, Sweta ^a   Whetstine, Johnathan R ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DNA;

ADAPTIVE IMMUNITY; ARTICLE; BACTERIUM; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOGENESIS; CHROMOSOME NUMBER; COPY NUMBER VARIATION; DEVELOPMENTAL BIOLOGY; DISEASE ASSOCIATION; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMAN; NEOPLASM; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; TRANSIENT SITE SPECIFIC COPY GAIN; TREATMENT RESPONSE; ADAPTATION; ANIMAL; CHROMOSOME ABERRATION; DRUG RESISTANCE; GENE DOSAGE; GENETIC VARIATION; GENETICS;

ADAPTATION, BIOLOGICAL; ANIMALS; CHROMOSOME ABERRATIONS; DRUG RESISTANCE; GENE DOSAGE; GENETIC HETEROGENEITY; GENOMIC STRUCTURAL VARIATION; HUMANS; NEOPLASMS;

EID: 84962184062     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00652-15     Document Type: Article

References (191)

1. Reich DE, Schaffner SF, Daly MJ, McVean G, Mullikin JC, Higgins JM, Richter DJ, Lander ES, Altshuler D. 2002. Human genome sequence variation and the influence of gene history, mutation and recombination. Nat Genet 32:135-142. http://dx.doi.org/10.1038/ng947.
2. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, Devon K, Dewar K, Doyle M, FitzHugh W, Funke R, Gage D, Harris K, Heaford A, Howland J, Kann L, Lehoczky J, LeVine R, McEwan P, McKernan K, Meldrim J, Mesirov JP, Miranda C, Morris W, Naylor J, Raymond C, Rosetti M, Santos R, Sheridan A, Sougnez C, Stange-Thomann Y, Stojanovic N, Subramanian A, Wyman D, Rogers J, Sulston J, Ainscough R, Beck S, Bentley D, Burton J, Clee C, Carter N, Coulson A, Deadman R, Deloukas P, Dunham A, Dunham I, Durbin R, French L, Grafham D, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409:860-921. http://dx.doi.org/10.1038/35057062.
3. Wheeler DA, Srinivasan M, Egholm M, Shen Y, Chen L, McGuire A, He W, Chen YJ, Makhijani V, Roth GT, Gomes X, Tartaro K, Niazi F, Turcotte CL, Irzyk GP, Lupski JR, Chinault C, Song XZ, Liu Y, Yuan Y, Nazareth L, Qin X, Muzny DM, Margulies M, Weinstock GM, Gibbs RA, Rothberg JM. 2008. The complete genome of an individual by massively parallel DNA sequencing. Nature 452:872-876. http://dx.doi.org/10.1038/nature06884.
4. Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, Haugen E, Hayden H, Albertson D, Pinkel D, Olson MV, Eichler EE.2005 Fine-scale structural variation of the human genome. Nat Genet 37:727-732. http://dx.doi.org/10.1038/ng1562.
5. Feuk L, Carson AR, Scherer SW. 2006. Structural variation in the human genome. Nat Rev Genet 7:85-97. http://dx.doi.org/10.1038/nrg1767.
6. Savage JR. 1977. Application of chromosome banding techniques to the study of primary chromosome structural changes. J Med Genet 14:362-370. http://dx.doi.org/10.1136/jmg.14.5.362.
7. Tang YC, Amon A. 2013. Gene copy-number alterations: a cost-benefit analysis. Cell 152:394-405. http://dx.doi.org/10.1016/j.cell.2012.11.043.
8. Torres EM, Williams BR, Amon A. 2008. Aneuploidy: cells losing their balance. Genetics 179:737-746. http://dx.doi.org/10.1534/genetics.108.090878.
9. Warburton D. 1991. De novo balanced chromosome rearrangements and extra marker chromosomes identified at prenatal diagnosis: clinical significance and distribution of breakpoints. Am J Hum Genet 49:995-1013.
10. Dumanski JP, Piotrowski A. 2012. Structural genetic variation in the context of somatic mosaicism. Methods Mol Biol 838:249-272. http://dx.doi.org/10.1007/978-1-61779-507-7_12.
11. Reams AB, Roth JR. 2015. Mechanisms of gene duplication and amplification. Cold Spring Harb Perspect Biol 7:a016592. http://dx.doi.org/10.1101/cshperspect.a016592.
12. Puig M, Casillas S, Villatoro S, Caceres M. 2015. Human inversions and their functional consequences. Brief Funct Genomics 14:369-379. http://dx.doi.org/10.1093/bfgp/elv020.
13. Alves JM, Lopes AM, Chikhi L, Amorim A. 2012. On the structural plasticity of the human genome: chromosomal inversions revisited. Curr Genomics 13:623-632. http://dx.doi.org/10.2174/138920212803759703.
14. Solinas-Toldo S, Lampel S, Stilgenbauer S, Nickolenko J, Benner A, Dohner H, Cremer T, Lichter P. 1997. Matrix-based comparative genomic hybridization: biochips to screen for genomic imbalances. Genes Chromosomes Cancer 20:399-407. http://dx.doi.org/10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.3.CO;2-l.
15. Speicher MR, Carter NP. 2005. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet 6:782-792. http://dx.doi.org/10.1038/nrg1692.
16. Pinkel D, Segraves R, Sudar D, Clark S, Poole I, Kowbel D, Collins C, Kuo WL, Chen C, Zhai Y, Dairkee SH, Ljung BM, Gray JW, Albertson DG. 1998. High resolution analysis ofDNAcopy number variation using comparative genomic hybridization to microarrays. Nat Genet 20:207-211. http://dx.doi.org/10.1038/2524.
17. Mullaney JM, Mills RE, Pittard WS, Devine SE. 2010. Small insertions and deletions (INDELs) in human genomes. Hum Mol Genet 19:R131-R136. http://dx.doi.org/10.1093/hmg/ddq400.
18. Mills RE, Luttig CT, Larkins CE, Beauchamp A, Tsui C, Pittard WS, Devine SE. 2006. An initial map of insertion and deletion (INDEL) variation in the human genome. Genome Res 16:1182-1190. http://dx.doi.org/10.1101/gr.4565806.
19. Levy S, Sutton G, Ng PC, Feuk L, Halpern AL, Walenz BP, Axelrod N, Huang J, Kirkness EF, Denisov G, Lin Y, MacDonald JR, Pang AW, Shago M, Stockwell TB, Tsiamouri A, Bafna V, Bansal V, Kravitz SA, Busam DA, Beeson KY, McIntosh TC, Remington KA, Abril JF, Gill J, Borman J, Rogers YH, Frazier ME, Scherer SW, Strausberg RL, Venter JC. 2007. The diploid genome sequence of an individual human. PLoS Biol 5:e254. http://dx.doi.org/10.1371/journal.pbio.0050254.
20. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. 2006. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet 38:75-81. http://dx.doi.org/10.1038/ng1697.
21. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, Gonzalez JR, Gratacos M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, Zhang J, Zerjal T, Armengol L, Conrad DF, Estivill X, Tyler-Smith C, Carter NP, Aburatani H, Lee C, Jones KW, Scherer SW, Hurles ME. 2006. Global variation in copy number in the human genome. Nature 444:444-454. http://dx.doi.org/10.1038/nature05329.
22. McCarroll SA, Kuruvilla FG, Korn JM, Cawley S, Nemesh J, Wysoker A, Shapero MH, de Bakker PI, Maller JB, Kirby A, Elliott AL, Parkin M, Hubbell E, Webster T, Mei R, Veitch J, Collins PJ, Handsaker R, Lincoln S, Nizzari M, Blume J, Jones KW, Rava R, Daly MJ, Gabriel SB, Altshuler D. 2008. Integrated detection and population-genetic analysis of SNPs and copy number variation. Nat Genet 40:1166-1174. http://dx.doi.org/10.1038/ng.238.
23. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, Scherer SW, Lee C. 2004. Detection of large-scale variation in the human genome. Nat Genet 36:949-951. http://dx.doi.org/10.1038/ng1416.
24. Sebat J, Lakshmi B, Troge J, Alexander J, Young J, Lundin P, Maner S, Massa H, Walker M, Chi M, Navin N, Lucito R, Healy J, Hicks J, Ye K, Reiner A, Gilliam TC, Trask B, Patterson N, Zetterberg A, Wigler M. 2004. Large-scale copy number polymorphism in the human genome. Science 305:525-528. http://dx.doi.org/10.1126/science.1098918.
25. International HapMap Consortium. 2005. A haplotype map of the human genome. Nature 437:1299-1320. http://dx.doi.org/10.1038/nature04226.
26. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA, Hurles ME, McVean GA. 2010. A map of human genome variation Int http://dx.doi.org/10.1038/nature09534.
27. Sudmant PH, Mallick S, Nelson BJ, Hormozdiari F, Krumm N, Huddleston J, Coe BP, Baker C, Nordenfelt S, Bamshad M, Jorde LB, Posukh OL, Sahakyan H, Watkins WS, Yepiskoposyan L, Abdullah MS, Bravi CM, Capelli C, Hervig T, Wee JT, Tyler-Smith C, van Driem G, Romero IG, Jha AR, Karachanak-Yankova S, Toncheva D, Comas D, Henn B, Kivisild T, Ruiz-Linares A, Sajantila A, Metspalu E, Parik J, Villems R, Starikovskaya EB, Ayodo G, Beall CM, Di Rienzo A, Hammer MF, Khusainova R, Khusnutdinova E, Klitz W, Winkler C, Labuda D, Metspalu M, Tishkoff SA, Dryomov S, Sukernik R, Patterson N, Reich D, et al. 2015. Global diversity, population stratification, and selection of human copy-number variation. Science 349: aab3761. http://dx.doi.org/10.1126/science.aab3761.
28. Zarrei M, MacDonald JR, Merico D, Scherer SW. 2015. A copy number variation map of the human genome. Nat Rev Genet 16:172-183. http://dx.doi.org/10.1038/nrg3871.
29. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CG, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R, Dante M, Fulton L, Hillier L, Waterston RH, McPherson JD, Gilman B, Schaffner S, Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933. http://dx.doi.org/10.1038/35057149.
30. Lee C, Iafrate AJ, Brothman AR. 2007. Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. Nat Genet 39: S48-S54. http://dx.doi.org/10.1038/ng2092.
31. Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, Slade D, Burchard J, Dow S, Ward TR, Kidd MJ, Friend SH, Marton MJ. 2000. Widespread aneuploidy revealed by DNA microarray expression profiling. Nat Genet 25:333-337. http://dx.doi.org/10.1038/77116.
32. Gordon DJ, Resio B, Pellman D. 2012. Causes and consequences of aneuploidy in cancer. Nat Rev Genet 13:189-203. http://dx.doi.org/10.1038/nrg3123.
33. Hastings PJ, Lupski JR, Rosenberg SM, Ira G. 2009. Mechanisms of change in gene copy number. Nat Rev Genet 10:551-564. http://dx.doi.org/10.1038/nrg2593.
34. Wheeler E, Huang N, Bochukova EG, Keogh JM, Lindsay S, Garg S, Henning E, Blackburn H, Loos RJ, Wareham NJ, O'Rahilly S, Hurles ME, Barroso I, Farooqi IS. 2013. Genome-wide SNP and CNV analysis identifies common and low-frequency variants associated with severe early-onset obesity. Nat Genet 45:513-517. http://dx.doi.org/10.1038/ng.2607.
35. Cooper NJ, Shtir CJ, Smyth DJ, Guo H, Swafford AD, Zanda M, Hurles ME, Walker NM, Plagnol V, Cooper JD, Howson JM, Burren OS, Onengut-Gumuscu S, Rich SS, Todd JA. 2015. Detection and correction of artefacts in estimation of rare copy number variants and analysis of rare deletions in type 1 diabetes. Hum Mol Genet 24:1774-1790 http://dx.doi.org/10.1093/hmg/ddu581.
36. Mitchell E, Douglas A, Kjaegaard S, Callewaert B, Vanlander A, Janssens S, Lawson Yuen A, Skinner C, Failla P, Alberti A, Avola E, Fichera M, Kibaek M, Digilio MC, Hannibal MC, den Hollander NS, Bizzarri V, Renieri A, Mencarelli MA, Fitzgerald T, Piazzolla S, van Oudenhove E, Romano C, Schwartz C, Eichler EE, Slavotinek A, Escobar L, Rajan D, Crolla J, Carter N, Hodge JC, Mefford HC. 2015. Recurrent duplications of 17q12 associated with variable phenotypes. Am J Med Genet A 167:3038-3045. http://dx.doi.org/10.1002/ajmg.a.37351.
37. Malhotra D, Sebat J. 2012. CNVs: harbingers of a rare variant revolution in psychiatric genetics. Cell 148:1223-1241. http://dx.doi.org/10.1016/j.cell.2012.02.039.
38. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-Martin C, Walsh T, Yamrom B, Yoon S, Krasnitz A, Kendall J, Leotta A, Pai D, Zhang R, Lee YH, Hicks J, Spence SJ, Lee AT, Puura K, Lehtimaki T, Ledbetter D, Gregersen PK, Bregman J, Sutcliffe JS, Jobanputra V, Chung W, Warburton D, King MC, Skuse D, Geschwind DH, Gilliam TC, Ye K, Wigler M. 2007. Strong association of de novo copy number mutations with autism. Science 316:445-449. http://dx.doi.org/10.1126/science.1138659.
39. International Schizophrenia Consortium. 2008. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature 455:237-241. http://dx.doi.org/10.1038/nature07239.
40. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261:921-923. http://dx.doi.org/10.1126/science.8346443.
41. Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM, Foroud T, Mayeux R, Saykin AJ. 2012. Analysis of copy number variation in Alzheimer's disease: the NIALOAD/NCRAD Family Study. Curr Alzheimer Res 9:801-814. http://dx.doi.org/10.2174/156720512802455331.
42. Krepischi AC, Pearson PL, Rosenberg C. 2012. Germline copy number variations and cancer predisposition. Future Oncol 8:441-450. http://dx.doi.org/10.2217/fon.12.34.
43. Colnaghi R, Carpenter G, Volker M, O'Driscoll M. 2011. The consequences of structural genomic alterations in humans: genomic disorders, genomic instability and cancer. Semin Cell Dev Biol 22:875-885. http://dx.doi.org/10.1016/j.semcdb.2011.07.010.
44. Speleman F, Kumps C, Buysse K, Poppe B, Menten B, De Preter K.2008 Copy number alterations and copy number variation in cancer: close encounters of the bad kind. Cytogenet Genome Res 123:176-182. http://dx.doi.org/10.1159/000184706.
45. Piotrowski A, Bruder CE, Andersson R, Diaz de Stahl T, Menzel U, Sandgren J, Poplawski A, von Tell D, Crasto C, Bogdan A, Bartoszewski R, Bebok Z, Krzyzanowski M, Jankowski Z, Partridge EC, Komorowski J, Dumanski JP. 2008. Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat 29:1118-1124 http://dx.doi.org/10.1002/humu.20815.
46. Youssoufian H, Pyeritz RE. 2002. Mechanisms and consequences of somatic mosaicism in humans. Nat Rev Genet 3:748-758. http://dx.doi.org/10.1038/nrg906.
47. Kim PM, Lam HY, Urban AE, Korbel JO, Affourtit J, Grubert F, Chen X, Weissman S, Snyder M, Gerstein MB. 2008. Analysis of copy number variants and segmental duplications in the human genome: evidence for a change in the process of formation in recent evolutionary history. Genome Res 18:1865-1874. http://dx.doi.org/10.1101/gr.081422.108.
48. Cheng Z, Ventura M, She X, Khaitovich P, Graves T, Osoegawa K, Church D, DeJong P, Wilson RK, Paabo S, Rocchi M, Eichler EE.2005 A genome-wide comparison of recent chimpanzee and human segmental duplications. Nature 437:88-93. http://dx.doi.org/10.1038/nature04000.
49. She X, Jiang Z, Clark RA, Liu G, Cheng Z, Tuzun E, Church DM, Sutton G, Halpern AL, Eichler EE. 2004. Shotgun sequence assembly and recent segmental duplications within the human genome. Nature 431:927-930. http://dx.doi.org/10.1038/nature03062.
50. Bailey JA, Gu Z, Clark RA, Reinert K, Samonte RV, Schwartz S, Adams MD, Myers EW, Li PW, Eichler EE. 2002. Recent segmental duplications in the human genome. Science 297:1003-1007. http://dx.doi.org/10.1126/science.1072047.
51. Thompson SL, Compton DA. 2011. Chromosome missegregation in human cells arises through specific types of kinetochore-microtubule attachment errors. Proc Natl Acad Sci U S A 108:17974-17978. http://dx.doi.org/10.1073/pnas.1109720108.
52. Buongiorno-Nardelli M, Amaldi F, Lava-Sanchez PA. 1976. Electron microscope analysis of amplifying ribosomal DNA from Xenopus laevis. Exp Cell Res 98:95-103. http://dx.doi.org/10.1016/0014-4827(76)90467-5.
53. Boseley P, Moss T, Machler M, Portmann R, Birnstiel M. 1979. Sequence organization of the spacer DNA in a ribosomal gene unit of Xenopus laevis. Cell 17:19-31. http://dx.doi.org/10.1016/0092-8674(79)90291-5.
54. Bird AP, Birnstiel ML. 1971. The relationship between protein synthesis and ribosomal DNA amplification in Xenopus laevis. Biochim Biophys Acta 247:157-163. http://dx.doi.org/10.1016/0005-2787(71)90819-7.
55. Brown DD, Dawid IB. 1968. Specific gene amplification in oocytes. Oocyte nuclei contain extrachromosomal replicas of the genes for ribosomal RNA. Science 160:272-280.
56. Gall JG, Rochaix JD. 1974. The amplified ribosomal DNA of dytiscid beetles. Proc Natl Acad Sci U S A 71:1819-1823. http://dx.doi.org/10.1073/pnas.71.5.1819.
57. Findly RC, Gall JG. 1978. Free ribosomal RNA genes in Paramecium are tandemly repeated. Proc Natl Acad SciUSA75:3312-3316. http://dx.doi.org/10.1073/pnas.75.7.3312.
58. Engberg J. 1985. The ribosomal RNA genes of Tetrahymena: structure and function. Eur J Cell Biol 36:133-151.
59. Lara FJ, Stocker AJ, Amabis JM. 1991. DNA sequence amplification in sciarid flies: results and perspectives. Braz J Med Biol Res 24:233-248.
60. Candido-Silva JA, Machado MC, Hartfelder KH, de Almeida JC, Paco-Larson ML, Monesi N. 2015. Amplification and expression of a salivary glandDNApuff gene in the prothoracic gland of Bradysia hygida (Diptera: Sciaridae). J Insect Physiol 74C:30-37.
61. Orr-Weaver TL. 1991. Drosophila chorion genes: cracking the eggshell's secrets. Bioessays 13:97-105. http://dx.doi.org/10.1002/bies.950130302.
62. Claycomb JM, Benasutti M, Bosco G, Fenger DD, Orr-Weaver TL.2004 Gene amplification as a developmental strategy: isolation of two developmental amplicons in Drosophila. Dev Cell 6:145-155. http://dx.doi.org/10.1016/S1534-5807(03)00398-8.
63. Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J. 2001. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci U S A 98:13361-13366. http://dx.doi.org/10.1073/pnas.231487398.
64. Blaschke AJ, Staley K, Chun J. 1996. Widespread programmed cell death in proliferative and postmitotic regions of the fetal cerebral cortex. Development 122:1165-1174.
65. Westra JW, Peterson SE, Yung YC, Mutoh T, Barral S, Chun J. 2008. Aneuploid mosaicism in the developing and adult cerebellar cortex. J Comp Neurol 507:1944-1951. http://dx.doi.org/10.1002/cne.21648.
66. McConnell MJ, Lindberg MR, Brennand KJ, Piper JC, Voet T, Cowing-Zitron C, Shumilina S, Lasken RS, Vermeesch JR, Hall IM, Gage FH. 2013. Mosaic copy number variation in human neurons. Science 342:632-637. http://dx.doi.org/10.1126/science.1243472.
67. Henrichsen CN, Vinckenbosch N, Zollner S, Chaignat E, Pradervand S, Schutz F, Ruedi M, Kaessmann H, Reymond A. 2009. Segmental copy number variation shapes tissue transcriptomes. Nat Genet 41:424-429. http://dx.doi.org/10.1038/ng.345.
68. Duncan AW, Taylor MH, Hickey RD, Hanlon Newell AE, Lenzi ML, Olson SB, Finegold MJ, Grompe M. 2010. The ploidy conveyor of mature hepatocytes as a source of genetic variation. Nature 467:707-710. http://dx.doi.org/10.1038/nature09414.
69. Duncan AW, Hanlon Newell AE, Smith L, Wilson EM, Olson SB, Thayer MJ, Strom SC, Grompe M. 2012. Frequent aneuploidy among normal human hepatocytes. Gastroenterology 142:25-28. http://dx.doi.org/10.1053/j.gastro.2011.10.029.
70. Knouse KA, Wu J, Whittaker CA, Amon A. 2014. Single cell sequencing reveals low levels of aneuploidy across mammalian tissues. Proc Natl Acad Sci U S A 111:13409-13414. http://dx.doi.org/10.1073/pnas.1415287111.
71. Guiral S, Mitchell TJ, Martin B, Claverys JP. 2005. Competenceprogrammed predation of noncompetent cells in the human pathogen Streptococcus pneumoniae: genetic requirements. Proc Natl Acad Sci U S A 102:8710-8715. http://dx.doi.org/10.1073/pnas.0500879102.
72. Slager J, Kjos M, Attaiech L, Veening JW. 2014. Antibiotic-induced replication stress triggers bacterial competence by increasing gene dosage near the origin. Cell 157:395-406. http://dx.doi.org/10.1016/j.cell.2014.01.068.
73. Sun S, Berg OG, Roth JR, Andersson DI. 2009. Contribution of gene amplification to evolution of increased antibiotic resistance in Salmonella typhimurium. Genetics 182:1183-1195. http://dx.doi.org/10.1534/genetics.109.103028.
74. Matagne A, Lamotte-Brasseur J, Frere JM. 1998. Catalytic properties of class A beta-lactamases: efficiency and diversity. Biochem J 330:581-598. http://dx.doi.org/10.1042/bj3300581.
75. Matagne A, Misselyn-Bauduin AM, Joris B, Erpicum T, Granier B, Frere JM. 1990. The diversity of the catalytic properties of class A beta-lactamases. Biochem J 265:131-146. http://dx.doi.org/10.1042/bj2650131.
76. Sandegren L, Andersson DI. 2009. Bacterial gene amplification: implications for the evolution of antibiotic resistance. Nat Rev Microbiol 7:578-588. http://dx.doi.org/10.1038/nrmicro2174.
77. Forche A, Magee PT, Selmecki A, Berman J, May G. 2009. Evolution in Candida albicans populations during a single passage through a mouse host. Genetics 182:799-811. http://dx.doi.org/10.1534/genetics.109.103325.
78. Hill JA, Ammar R, Torti D, Nislow C, Cowen LE. 2013. Genetic and genomic architecture of the evolution of resistance to antifungal drug combinations. PLoS Genet 9:e1003390. http://dx.doi.org/10.1371/journal.pgen.1003390.
79. Ford CB, Funt JM, Abbey D, Issi L, Guiducci C, Martinez DA, Delorey T, Li BY, White TC, Cuomo C, Rao RP, Berman J, Thompson DA, Regev A. 2015. The evolution of drug resistance in clinical isolates of Candida albicans. eLife 4:e00662. http://dx.doi.org/10.7554/eLife.00662.
80. Morrow CA, Fraser JA. 2013. Ploidy variation as an adaptive mechanism in human pathogenic fungi. Semin Cell Dev Biol 24:339-346. http://dx.doi.org/10.1016/j.semcdb.2013.01.008.
81. Selmecki A, Forche A, Berman J. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science 313:367-370. http://dx.doi.org/10.1126/science.1128242.
82. Selmecki A, Gerami-Nejad M, Paulson C, Forche A, Berman J. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol 68:624-641. http://dx.doi.org/10.1111/j.1365-2958.2008.06176.x.
83. Coste AT, Karababa M, Ischer F, Bille J, Sanglard D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicansABCtransportersCDR1and CDR2. Eukaryot Cell 3:1639-1652. http://dx.doi.org/10.1128/EC.3.6.1639-1652.2004.
84. White TC. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41:1482-1487.
85. Gresham D, Desai MM, Tucker CM, Jenq HT, Pai DA, Ward A, DeSevo CG, Botstein D, Dunham MJ. 2008. The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. PLoS Genet 4:e1000303. http://dx.doi.org/10.1371/journal.pgen.1000303.
86. Perry GH, Dominy NJ, Claw KG, Lee AS, Fiegler H, Redon R, Werner J, Villanea FA, Mountain JL, Misra R, Carter NP, Lee C, Stone AC.2007 Diet and the evolution of human amylase gene copy number variation. Nat Genet 39:1256-1260. http://dx.doi.org/10.1038/ng2123.
87. Iskow RC, Gokcumen O, Lee C. 2012. Exploring the role of copy number variants in human adaptation. Trends Genet 28:245-257. http://dx.doi.org/10.1016/j.tig.2012.03.002.
88. Schrider DR, Hahn MW. 2010. Gene copy-number polymorphism in nature. Proc Biol Sci 277:3213-3221. http://dx.doi.org/10.1098/rspb.2010.1180.
89. Gonzalez E, Kulkarni H, Bolivar H, Mangano A, Sanchez R, Catano G, Nibbs RJ, Freedman BI, Quinones MP, Bamshad MJ, Murthy KK, Rovin BH, Bradley W, Clark RA, Anderson SA, O'Connell RJ, Agan BK, Ahuja SS, Bologna R, Sen L, Dolan MJ, Ahuja SK. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307:1434-1440. http://dx.doi.org/10.1126/science.1101160.
90. Hollox EJ, Huffmeier U, Zeeuwen PL, Palla R, Lascorz J, Rodijk-Olthuis D, van de Kerkhof PC, Traupe H, de Jongh G, den Heijer M, Reis A, Armour JA, Schalkwijk J. 2008. Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet 40:23-25. http://dx.doi.org/10.1038/ng.2007.48.
91. Hollox EJ, Barber JC, Brookes AJ, Armour JA. 2008. Defensins and the dynamic genome: what we can learn from structural variation at human chromosome band 8p23.1. Genome Res 18:1686-1697. http://dx.doi.org/10.1101/gr.080945.108.
92. Le Marechal C, Masson E, Chen JM, Morel F, Ruszniewski P, Levy P, Ferec C. 2006. Hereditary pancreatitis caused by triplication of the trypsinogen locus. Nat Genet 38:1372-1374. http://dx.doi.org/10.1038/ng1904.
93. Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF. 2006. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet 79:439-448. http://dx.doi.org/10.1086/505915.
94. Aitman TJ, Dong R, Vyse TJ, Norsworthy PJ, Johnson MD, Smith J, Mangion J, Roberton-Lowe C, Marshall AJ, Petretto E, Hodges MD, Bhangal G, Patel SG, Sheehan-Rooney K, Duda M, Cook PR, Evans DJ, Domin J, Flint J, Boyle JJ, Pusey CD, Cook HT. 2006. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 439:851-855. http://dx.doi.org/10.1038/nature04489.
95. Duncan AW, Hanlon Newell AE, Bi W, Finegold MJ, Olson SB, Beaudet AL, Grompe M. 2012. Aneuploidy as a mechanism for stressinduced liver adaptation. J Clin Invest 122:3307-3315. http://dx.doi.org/10.1172/JCI64026.
96. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, et al. 2010. The landscape of somatic copy-number alteration across human cancers. Nature 463:899-905. http://dx.doi.org/10.1038/nature08822.
97. Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabe RR, Bhan MK, Calvo F, Eerola I, Gerhard DS, Guttmacher A, Guyer M, Hemsley FM, Jennings JL, Kerr D, Klatt P, Kolar P, Kusada J, Lane DP, Laplace F, Youyong L, Nettekoven G, Ozenberger B, Peterson J, Rao TS, Remacle J, Schafer AJ, Shibata T, Stratton MR, Vockley JG, Watanabe K, Yang H, Yuen MM, Knoppers BM, Bobrow M, Cambon-Thomsen A, Dressler LG, Dyke SO, Joly Y, Kato K, Kennedy KL, Nicolas P, Parker MJ, Rial-Sebbag E, Romeo-Casabona CM, Shaw KM, Wallace S, Wiesner GL, Zeps N, Lichter P, et al. 2010. International network of cancer genome projects. Nature 464:993-998. http://dx.doi.org/10.1038/nature08987.
98. Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. 1987. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A 84:6899-6903. http://dx.doi.org/10.1073/pnas.84.19.6899.
99. Schwab M. 1990. Amplification of the MYCN oncogene and deletion of putative tumour suppressor gene in human neuroblastomas. Brain Pathol 1:41-46. http://dx.doi.org/10.1111/j.1750-3639.1990.tb00637.x.
100. Collins S, Groudine M. 1982. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature 298: 679-681. http://dx.doi.org/10.1038/298679a0.
101. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE. 1988. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48:1238-1243.
102. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712. http://dx.doi.org/10.1126/science.2470152.
103. Hynes NE. 1993. Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4:19-26.
104. Hollander MC, Blumenthal GM, Dennis PA. 2011. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer 11:289-301. http://dx.doi.org/10.1038/nrc3037.
105. Levine AJ, Momand J, Finlay CA. 1991. The p53 tumour suppressor gene. Nature 351:453-456. http://dx.doi.org/10.1038/351453a0.
106. Linehan WM, Lerman MI, Zbar B. 1995. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. JAMA 273:564-570.
107. Weinstein IB, Joe AK. 2006. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448-457. http://dx.doi.org/10.1038/ncponc0558.
108. Arteaga CL. 2003. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Res 5:96-100. http://dx.doi.org/10.1186/bcr574.
109. Minguet J, Smith KH, Bramlage P. 4 November 2015. Targeted therapies for treatment of non-small cell lung cancer: recent advances and future perspectives. Int J Cancer http://dx.doi.org/10.1002/ijc.29915.
110. Arteaga CL, Johnson DH. 2001. Tyrosine kinase inhibitors-ZD1839 (Iressa). Curr Opin Oncol 13:491-498. http://dx.doi.org/10.1097/00001622-200111000-00012.
111. Shaughnessy J. 2005. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 10(Suppl 1):117-126. http://dx.doi.org/10.1080/10245330512331390140.
112. Fonseca R, Van Wier SA, Chng WJ, Ketterling R, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. 2006. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20:2034-2040. http://dx.doi.org/10.1038/sj.leu.2404403.
113. Yin L, Kosugi M, Kufe D. 2012. Inhibition of the MUC1-C oncoprotein induces multiple myeloma cell death by down-regulating TIGAR expression and depleting NADPH. Blood 119:810-816. http://dx.doi.org/10.1182/blood-2011-07-369686.
114. Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jager D, Podar K. 2014. Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation. Cancer Lett 343:286-294. http://dx.doi.org/10.1016/j.canlet.2013.09.042.
115. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S, Taniwaki M, Inazawa J. 2004. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 165:71-81. http://dx.doi.org/10.1016/S0002-9440(10)63276-2.
116. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.2007 Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585-598. http://dx.doi.org/10.1038/nrc2189.
117. Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR. 2009. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res 69:7577-7586. http://dx.doi.org/10.1158/0008-5472.CAN-09-0773.
118. Fabris S, Ronchetti D, Agnelli L, Baldini L, Morabito F, Bicciato S, Basso D, Todoerti K, Lombardi L, Lambertenghi-Deliliers G, Neri A.2007 Transcriptional features of multiple myeloma patients with chromosome 1q gain. Leukemia 21:1113-1116. http://dx.doi.org/10.1038/sj.leu.2404616.
119. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR, Hollmig K, Zangarri M, Pineda-Roman M, van Rhee F, Cavallo F, Burington B, Crowley J, Tricot G, Barlogie B, Shaughnessy JD, Jr.2006 Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood 108:1724-1732 http://dx.doi.org/10.1182/blood-2006-03-009910.
120. Chang H, Yeung J, Xu W, Ning Y, Patterson B. 2006. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. Br J Haematol 134:613-615. http://dx.doi.org/10.1111/j.1365-2141.2006.06237.x.
121. Shi L, Wang S, Zangari M, Xu H, Cao TM, Xu C, Wu Y, Xiao F, Liu Y, Yang Y, Salama M, Li G, Tricot G, Zhan F. 2010. Over-expression of CKS1B activates both MEK/ERK and JAK/STAT3 signaling pathways and promotes myeloma cell drug-resistance. Oncotarget 1:22-33. http://dx.doi.org/10.18632/oncotarget.105.
122. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, et al. 2015. Wholegenome characterization of chemoresistant ovarian cancer. Nature 521: 489-494. http://dx.doi.org/10.1038/nature14410.
123. Noro R, Seike M, Zou F, Soeno C, Matsuda K, Sugano T, Nishijima N, Matsumoto M, Kitamura K, Kosaihira S, Minegishi Y, Yoshimura A, Kubota K, Gemma A. 2015. MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation. BMC Cancer 15:31. http://dx.doi.org/10.1186/s12885-015-1019-1.
124. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA, Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S.2013 Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 3:658-673. http://dx.doi.org/10.1158/2159-8290.CD-12-0558.
125. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Janne PA. 2007. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043. http://dx.doi.org/10.1126/science.1141478.
126. Huang J, Zhou Y, Thomas GS, Gu Z, Yang Y, Xu H, Tricot G, Zhan F. 2015. NEDD8 inhibition overcomes CKS1B-induced drug resistance by upregulation of p21 in multiple myeloma. Clin Cancer Res 21:5532-5542 http://dx.doi.org/10.1158/1078-0432.CCR-15-0254.
127. Pollett JB, Trudel S, Stern D, Li ZH, Stewart AK. 2002. Overexpression of the myeloma-associated oncogene fibroblast growth factor receptor 3 confers dexamethasone resistance. Blood 100:3819-3821. http://dx.doi.org/10.1182/blood-2002-02-0608.
128. Etemadmoghadam D, George J, Cowin PA, Cullinane C, Kansara M, Gorringe KL, Smyth GK, Bowtell DD. 2010. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One 5:e15498. http://dx.doi.org/10.1371/journal.pone.0015498.
129. Wang B, Li S, Meng X, Shang H, Guan Y. 2015. Inhibition of mdr1 by G-quadruplex oligonucleotides and reversal of paclitaxel resistance in human ovarian cancer cells. Tumour Biol 36:6433-6443. http://dx.doi.org/10.1007/s13277-015-3333-2.
130. Duan Z, Brakora KA, Seiden MV. 2004. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interferingRNAand reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 3:833-838.
131. Yabuki N, Sakata K, Yamasaki T, Terashima H, Mio T, Miyazaki Y, Fujii T, Kitada K. 2007. Gene amplification and expression in lung cancer cells with acquired paclitaxel resistance. Cancer Genet Cytogenet 173:1-9. http://dx.doi.org/10.1016/j.cancergencyto.2006.07.020.
132. Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA. 2012. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 4:120ra117.
133. Shattuck DL, Miller JK, Carraway KL, III, Sweeney C. 2008. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68:1471-1477. http://dx.doi.org/10.1158/0008-5472.CAN-07-5962.
134. White CD, Li Z, Dillon DA, Sacks DB. 2011. IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance. J Biol Chem 286:29734-29747. http://dx.doi.org/10.1074/jbc.M111.220939.
135. Wang TL, Diaz LA, Jr, Romans K, Bardelli A, Saha S, Galizia G, Choti M, Donehower R, Parmigiani G, Shih IM, Iacobuzio-Donahue C, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE. 2004. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A 101:3089-3094. http://dx.doi.org/10.1073/pnas.0308716101.
136. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880. http://dx.doi.org/10.1126/science.1062538.
137. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, Ng C, Chodon T, Scolyer RA, Dahlman KB, Sosman JA, Kefford RF, Long GV, Nelson SF, Ribas A, Lo RS. 2012. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 3:724. http://dx.doi.org/10.1038/ncomms1727.
138. Villanueva J, Infante JR, Krepler C, Reyes-Uribe P, Samanta M, Chen HY, Li B, Swoboda RK, Wilson M, Vultur A, Fukunaba-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser K, DeMarini DJ, Gilmer TM, Martin AM, Marmorstein R, Schultz DC, Speicher DW, Karakousis GC, Xu W, Amaravadi RK, Xu X, Schuchter LM, Herlyn M, Nathanson KL. 2013. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. Cell Rep 4:1090-1099. http://dx.doi.org/10.1016/j.celrep.2013.08.023.
139. Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, McHenry K, Porter D, Tran TN, Love KT, Langer R, Anderson DG, Garraway LA, Duncan LM, Morton DL, Hoon DS, Wargo JA, Song JS, Fisher DE. 2013. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A 110:4321-4326. http://dx.doi.org/10.1073/pnas.1205575110.
140. Horns RC, Jr, Dower WJ, Schimke RT. 1984. Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol 2:2-7.
141. Carman MD, Schornagel JH, Rivest RS, Srimatkandada S, Portlock CS, Duffy T, Bertino JR. 1984. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 2:16-20.
142. Kudoh K, Takano M, Koshikawa T, Hirai M, Yoshida S, Mano Y, Yamamoto K, Ishii K, Kita T, Kikuchi Y, Nagata I, Miwa M, Uchida K. 1999. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients. Clin Cancer Res 5:2526-2531.
143. Takano M, Kudo K, Goto T, Yamamoto K, Kita T, Kikuchi Y. 2001. Analyses by comparative genomic hybridization of genes relating with cisplatin-resistance in ovarian cancer. Hum Cell 14:267-271.
144. Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD. 2013. Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer. Clin Cancer Res 19:5960-5971. http://dx.doi.org/10.1158/1078-0432.CCR-13-1337.
145. Hakala MT. 1957. Prevention of toxicity of amethopterin for sarcoma-180 cells in tissue culture. Science 126:255.
146. Hakala MT, Taylor E. 1959. The ability of purine and thymine derivatives and of glycine to support the growth of mammalian cells in culture. J Biol Chem 234:126-128.
147. Hakala MT, Zakrzewski SF, Nichol CA. 1961. Relation of folic acid reductase to amethopterin resistance in cultured mammalian cells. J Biol Chem 236:952-958.
148. Fischer GA. 1961. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Biochem Pharmacol 7:75-77. http://dx.doi.org/10.1016/0006-2952(61)90128-9.
149. Schimke RT. 1986. Methotrexate resistance and gene amplification. Mechanisms and implications. Cancer 57:1912-1917.
150. Alt FW, Kellems RE, Bertino JR, Schimke RT. 1978. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells. J Biol Chem 253:1357-1370.
151. Biedler JL, Spengler BA. 1976. A novel chromosome abnormality in human neuroblastoma and antifolate-resistant Chinese hamster cell lives in culture. J Natl Cancer Inst 57:683-695.
152. Biedler JL, Spengler BA. 1976. Metaphase chromosome anomaly: association with drug resistance and cell-specific products. Science 191:185-187. http://dx.doi.org/10.1126/science.942798.
153. Haber DA, Schimke RT. 1981. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell 26:355-362. http://dx.doi.org/10.1016/0092-8674(81)90204-X.
154. Spriggs AI, Boddington MM, Clarke CM. 1962. Chromosomes of human cancer cells. Br Med J 2:1431-1435. http://dx.doi.org/10.1136/bmj.2.5317.1431.
155. Gebhart E. 2005. Double minutes, cytogenetic equivalents of gene amplification, in human neoplasia: a review. Clin Transl Oncol 7:477-485. http://dx.doi.org/10.1007/BF02717000.
156. Nunberg JH, Kaufman RJ, Schimke RT, Urlaub G, Chasin LA. 1978. Amplified dihydrofolate reductase genes are localized to a homogeneously staining region of a single chromosome in a methotrexateresistant Chinese hamster ovary cell line. Proc Natl Acad Sci U S A 75: 5553-5556. http://dx.doi.org/10.1073/pnas.75.11.5553.
157. Dolnick BJ, Berenson RJ, Bertino JR, Kaufman RJ, Nunberg JH, Schimke RT. 1979. Correlation of dihydrofolate reductase elevation with gene amplification in a homogeneously staining chromosomal region in L5178Y cells. J Cell Biol 83:394-402. http://dx.doi.org/10.1083/jcb.83.2.394.
158. Kaufman RJ, Brown PC, Schimke RT. 1979. Amplified dihydrofolate reductase genes in unstably methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci U S A 76:5669-5673 http://dx.doi.org/10.1073/pnas.76.11.5669.
159. Shimizu N. 2009. Extrachromosomal double minutes and chromosomal homogeneously staining regions as probes for chromosome research. Cytogenet Genome Res 124:312-326. http://dx.doi.org/10.1159/000218135.
160. Albertson DG. 2006. Gene amplification in cancer. Trends Genet 22: 447-455. http://dx.doi.org/10.1016/j.tig.2006.06.007.
161. Meng X, Qi X, Guo H, Cai M, Li C, Zhu J, Chen F, Li J, Zhao Y, Liu P, Jia X, Yu J, Zhang C, Sun W, Yu Y, Jin Y, Bai J, Wang M, Rosales J, Lee KY, Fu S. 2015. Novel role for non-homologous end joining in the formation of double minutes in methotrexate-resistant colon cancer cells. J Med Genet 52:135-144. http://dx.doi.org/10.1136/jmedgenet-2014-102703.
162. Storlazzi CT, Lonoce A, Guastadisegni MC, Trombetta D, D'Addabbo P, Daniele G, L'Abbate A, Macchia G, Surace C, Kok K, Ullmann R, Purgato S, Palumbo O, Carella M, Ambros PF, Rocchi M. 2010. Gene amplification as double minutes or homogeneously staining regions in solid tumors: origin and structure. Genome Res 20:1198-1206. http://dx.doi.org/10.1101/gr.106252.110.
163. Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, Kovar H, Gadner H, Ambros PF. 1997. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation: sign of tumour cell revertance? Eur J Cancer 33:2043-2049. http://dx.doi.org/10.1016/S0959-8049(97)00204-9.
164. Narath R, Ambros IM, Kowalska A, Bozsaky E, Boukamp P, Ambros PF. 2007. Induction of senescence in MYCN amplified neuroblastoma cell lines by hydroxyurea. Genes Chromosomes Cancer 46:130-142. http://dx.doi.org/10.1002/gcc.20393.
165. Balaban-Malenbaum G, Gilbert F. 1977. Double minute chromosomes and the homogeneously staining regions in chromosomes of a human neuroblastoma cell line. Science 198:739-741. http://dx.doi.org/10.1126/science.71759.
166. Benner SE, Wahl GM, Von Hoff DD. 1991. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs 2:11-25. http://dx.doi.org/10.1097/00001813-199102000-00002.
167. Nielsen JL, Walsh JT, Degen DR, Drabek SM, McGill JR, von Hoff DD. 1993. Evidence of gene amplification in the form of double minute chromosomes is frequently observed in lung cancer. Cancer Genet Cytogenet 65:120-124. http://dx.doi.org/10.1016/0165-4608(93)90219-C.
168. Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. 1983. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 305:245-248. http://dx.doi.org/10.1038/305245a0.
169. Von Hoff DD, McGill JR, Forseth BJ, Davidson KK, Bradley TP, Van Devanter DR, Wahl GM. 1992. Elimination of extrachromosomally amplified MYC genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad SciUSA89:8165-8169. http://dx.doi.org/10.1073/pnas.89.17.8165.
170. Eckhardt SG, Dai A, Davidson KK, Forseth BJ, Wahl GM, Von Hoff DD. 1994. Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci U S A 91: 6674-6678. http://dx.doi.org/10.1073/pnas.91.14.6674.
171. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS.2014 Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science 343:72-76. http://dx.doi.org/10.1126/science.1241328.
172. Gajadhar AS, Bogdanovic E, Munoz DM, Guha A. 2012. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol Cancer Res 10:428-440. http://dx.doi.org/10.1158/1541-7786.MCR-11-0531.
173. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. 2012. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458-471. http://dx.doi.org/10.1158/2159-8290.CD-11-0284.
174. Black JC, Atabakhsh E, Kim J, Biette KM, Van Rechem C, Ladd B, Burrowes PD, Donado C, Mattoo H, Kleinstiver BP, Song B, Andriani G, Joung JK, Iliopoulos O, Montagna C, Pillai S, Getz G, Whetstine JR.2015 Hypoxia drives transient site-specific copy gain and drug-resistant gene expression. Genes Dev 29:1018-1031. http://dx.doi.org/10.1101/gad.259796.115.
175. Black JC, Manning AL, Van Rechem C, Kim J, Ladd B, Cho J, Pineda CM, Murphy N, Daniels DL, Montagna C, Lewis PW, Glass K, Allis CD, Dyson NJ, Getz G, Whetstine JR. 2013. KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors. Cell 154:541-555. http://dx.doi.org/10.1016/j.cell.2013.06.051.
176. MacAlpine DM, Almouzni G. 2013. Chromatin and DNA replication. Cold Spring Harb Perspect Biol 5:a010207. http://dx.doi.org/10.1101/cshperspect.a010207.
177. Truong LN, Wu X. 2011. Prevention of DNA re-replication in eukaryotic cells. J Mol Cell Biol 3:13-22. http://dx.doi.org/10.1093/jmcb/mjq052.
178. Chen Z, Zang J, Whetstine J, Hong X, Davrazou F, Kutateladze TG, Simpson M, Mao Q, Pan CH, Dai S, Hagman J, Hansen K, Shi Y, Zhang G. 2006. Structural insights into histone demethylation by JMJD2 family members. Cell 125:691-702. http://dx.doi.org/10.1016/j.cell.2006.04.024.
179. Whetstine JR, Nottke A, Lan F, Huarte M, Smolikov S, Chen Z, Spooner E, Li E, Zhang G, Colaiacovo M, Shi Y. 2006. Reversal of histone lysine trimethylation by the JMJD2 family of histone demethylases. Cell 125:467-481. http://dx.doi.org/10.1016/j.cell.2006.03.028.
180. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J, Antal T, Hansen KH, Helin K. 2006. The putative oncogene GASC1 demethylates tri-and dimethylated lysine 9 on histone H3. Nature 442:307-311. http://dx.doi.org/10.1038/nature04837.
181. Klose RJ, Yamane K, Bae Y, Zhang D, Erdjument-Bromage H, Tempst P, Wong J, Zhang Y. 2006. The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. Nature 442: 312-316. http://dx.doi.org/10.1038/nature04853.
182. Lan F, Nottke AC, Shi Y. 2008. Mechanisms involved in the regulation of histone lysine demethylases. Curr Opin Cell Biol 20:316-325. http://dx.doi.org/10.1016/j.ceb.2008.03.004.
183. Black JC, Allen A, Van Rechem C, Forbes E, Longworth M, Tschop K, Rinehart C, Quiton J, Walsh R, Smallwood A, Dyson NJ, Whetstine JR. 2010. Conserved antagonism between JMJD2A/KDM4A and HP1γ during cell cycle progression. Mol Cell 40:736-748. http://dx.doi.org/10.1016/j.molcel.2010.11.008.
184. 2 too much gain. Cell Cycle 14:2869-2870. http://dx.doi.org/10.1080/15384101.2015.1076659.
185. Martin-Ezquerra G, Salgado R, Toll A, Baro T, Mojal S, Yebenes M, Garcia-Muret MP, Sole F, Quitllet FA, Espinet B, Pujol RM. 2011. CDC28 protein kinase regulatory subunit 1B (CKS1B) expression and genetic status analysis in oral squamous cell carcinoma. Histol Histopathol 26:71-77.
186. Smith EH, Janknecht R, Maher LJ, III. 2007. Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma. Hum Mol Genet 16:3136-3148. http://dx.doi.org/10.1093/hmg/ddm275.
187. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, Raine K, Jones D, Marshall J, Ramakrishna M, Shlien A, Cooke SL, Hinton J, Menzies A, Stebbings LA, Leroy C, Jia M, Rance R, Mudie LJ, Gamble SJ, Stephens PJ, McLaren S, Tarpey PS, Papaemmanuil E, Davies HR, Varela I, McBride DJ, Bignell GR, Leung K, Butler AP, Teague JW, Martin S, Jonsson G, Mariani O, Boyault S, Miron P, Fatima A, Langerod A, Aparicio SA, Tutt A, Sieuwerts AM, Borg A, Thomas G, Salomon AV, Richardson AL, Borresen-Dale AL, Futreal PA, Stratton MR, Campbell PJ. 2012. The life history of 21 breast cancers. Cell 149:994-1007. http://dx.doi.org/10.1016/j.cell.2012.04.023.
188. Morrison CD, Liu P, Woloszynska-Read A, Zhang J, Luo W, Qin M, Bshara W, Conroy JM, Sabatini L, Vedell P, Xiong D, Liu S, Wang J, Shen H, Li Y, Omilian AR, Hill A, Head K, Guru K, Kunnev D, Leach R, Eng KH, Darlak C, Hoeflich C, Veeranki S, Glenn S, You M, Pruitt SC, Johnson CS, Trump DL. 2014. Whole-genome sequencing identifies genomic heterogeneity at a nucleotide and chromosomal level in bladder cancer. Proc Natl Acad Sci U S A 111:E672-E681. http://dx.doi.org/10.1073/pnas.1313580111.
189. Burrell RA, McGranahan N, Bartek J, Swanton C. 2013. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 501: 338-345. http://dx.doi.org/10.1038/nature12625.
190. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan Y, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. 2013. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152:714-726. http://dx.doi.org/10.1016/j.cell.2013.01.019.
191. Black JC, Zhang H, Kim J, Getz G, Whetstine JR. 11 January 2016. Regulation of transient site-specific copy gain by microRNA. J Biol Chem http://dx.doi.org/10.1074/jbc.M115.711648.